tradingkey.logo
tradingkey.logo
Pesquisar

STAAR Surgical Co

STAA
Adicionar à lista de desejos
27.790USD
-0.360-1.28%
Fechamento 07/02, 13:00ETCotações atrasadas em 15 min
1.38BValor de mercado
PerdaP/L TTM

Mais detalhes de STAAR Surgical Co Empresa

STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. The Company markets and sells its ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. Its EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The Company's newest offering, EVO Viva, has an extended depth of focus (EDoF) optic, which is designed to treat myopia with presbyopia (age-related loss of ability to focus). It also market and sell an ICL lens to treat hyperopia (farsightedness), called Visian ICL. It makes its ICL product offerings available in multiple models, powers and lengths, including some with toric ICL (TICL) versions to correct for astigmatism (blurred vision). The Company’s principal products are ICLs used in refractive surgery, including its EVO family of lenses.

Informações de STAAR Surgical Co

Código da empresaSTAA
Nome da EmpresaSTAAR Surgical Co
Data de listagemFeb 24, 1992
CEOFarrell (Stephen C)
Número de funcionários1157
Tipo de títulosOrdinary Share
Fim do ano fiscalFeb 24
Endereço1911 Walker Ave
CidadeMONROVIA
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal91016
Telefone16263037902
Sitehttps://www.staar.com/
Código da empresaSTAA
Data de listagemFeb 24, 1992
CEOFarrell (Stephen C)

Executivos da empresa STAAR Surgical Co

Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Stephen C. (Steve) Farrell, CPA
Mr. Stephen C. (Steve) Farrell, CPA
Chief Executive Officer, Director
Chief Executive Officer, Director
82.21K
+57.24%
Mr. Wei Jiang
Mr. Wei Jiang
Director
Director
78.19K
+13.66%
Mr. Warren Foust
Mr. Warren Foust
President, Chief Operating Officer
President, Chief Operating Officer
69.54K
+18.35%
Dr. Magda Michna, Ph.D.
Dr. Magda Michna, Ph.D.
Chief Development Officer
Chief Development Officer
33.42K
+25.17%
Mr. Nathaniel B. Sisitsky, Esq.
Mr. Nathaniel B. Sisitsky, Esq.
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
30.18K
+72.87%
Ms. Deborah J. Andrews
Ms. Deborah J. Andrews
Chief Financial Officer
Chief Financial Officer
18.65K
+53.97%
Mr. Louis E. (Lou) Silverman
Mr. Louis E. (Lou) Silverman
Independent Director
Independent Director
11.16K
+95.74%
Dr. Elizabeth Yeu, M.D.
Dr. Elizabeth Yeu, M.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
5.10K
--
Mr. Brian Moore
Mr. Brian Moore
Vice President - Investor Relations and Corporate Development
Vice President - Investor Relations and Corporate Development
--
--
Ms. Lilian Zhou
Ms. Lilian Zhou
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Stephen C. (Steve) Farrell, CPA
Mr. Stephen C. (Steve) Farrell, CPA
Chief Executive Officer, Director
Chief Executive Officer, Director
82.21K
+57.24%
Mr. Wei Jiang
Mr. Wei Jiang
Director
Director
78.19K
+13.66%
Mr. Warren Foust
Mr. Warren Foust
President, Chief Operating Officer
President, Chief Operating Officer
69.54K
+18.35%
Dr. Magda Michna, Ph.D.
Dr. Magda Michna, Ph.D.
Chief Development Officer
Chief Development Officer
33.42K
+25.17%
Mr. Nathaniel B. Sisitsky, Esq.
Mr. Nathaniel B. Sisitsky, Esq.
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
30.18K
+72.87%
Ms. Deborah J. Andrews
Ms. Deborah J. Andrews
Chief Financial Officer
Chief Financial Officer
18.65K
+53.97%

Perguntas frequentes

Quem são os cinco principais acionistas de STAAR Surgical Co?

Os cinco principais acionistas de STAAR Surgical Co são: Mr. Stephen C. (Steve) Farrell, CPA

Quantas instituições possuem ações da STAAR Surgical Co (STAA)?

Em 2026Q1, 543 instituições possuíam ações da STAAR Surgical Co, com valor de mercado aproximado de 58.06M, representando 116.62% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -10575638.00.